Icon

Yondelis - (1 mg/ Vial; Powder, Intravenous)

Trabectedin Janssen Pharma
1 mg/ Vial; Powder, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
YONDELIS is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1) Neutropenic sepsis: Severe, and fatal, neutropenic sepsis may occur
Yes
*** *********** ******* **- **** ***** **** ******* *** ***** *** ****. **** ***** * **** ** ** ****** '***, '*** *** *** *********. ** ****** **** **** **** ****** ** *** ****. ***** ** **** **, **** ***** *** *** ****** **** ** ****** '***. *** **** **** ***** * **** ** *** *** *********. ***** (***) ******** ********* ******** ****** ** ****** **** ****** ****, *** ** ** ******** *** ***-*** ***********.
Yondelis Patent 1 Patent 2
******* ****** ********* ** **** *** *******
*** - ***** ******* *********
*** **** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* ****** *** \ ********* *** **, **** ********* ** *** *** / ******* **** ***** *** **, ****
*** - ***** *** \ *** *** **, **** ******* ********* ******** ** ** ****
*** **** ** \ ** *** *, **** ******* ********* ******** ***** ***-**** ***********
  1. *** **, **** : * **** ** ** ***** *** ***** *** *** *** *********.
  2. *** **, **** : ******* (******)******** ******* ***** **'* **** ** ****** ** ******* '*** *** '***
  3. *** *, **** : ***** (*** ******) ******** ******* ***** **'* **** ** ****** ** ******* '*** *** '***
  4. *** **, **** : ******* ***** * **** ******* ******* *** ***** ** ****** '*** *** '***
  5. *** *, **** : ******* *** ***** (***) ******* **** ********* *** ******* ********* ********** *.*.*. ****** '***.
  6. *** *, **** : ******* **** *** **** ** '*** *** '***.
  7. *** *, **** : ******* ***** * **** ******* *** **** ** ****** '*** *** '***
  8. *** *, **** : ******* ******* **** *** **** ** ******* *****.
  9. *** **, **** : ******* ********* ***** **** ** * **** *** ****** **** ****** '*** *** **, ******* ******* ********** **** *******.
  10. *** *, **** : ******* ******* ********** **** ***** (*** ******) ** ******* *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.